Drug Search Results
More Filters [+]

Dirucotide

Alternative Names: dirucotide, mbp-8298, mbp8298, mbp 8298
Latest Update: 2010-09-09
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Immunosuppressive Immuno

Novel Mechanism: Yes

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BioMS Technology Corp.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dirucotide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis

Phase 2: Multiple Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-001947-70

P2

Completed

Multiple Sclerosis

2009-09-25

MINDSET01

P3

Completed

Multiple Sclerosis, Relapsing-Remitting

2009-09-01

MAESTRO-02

P3

Terminated

Multiple Sclerosis, Chronic Progressive

2009-09-01

MAESTRO-03

P3

Terminated

Multiple Sclerosis, Chronic Progressive

2009-07-01

Recent News Events

Date

Type

Title